ANKTIVA- The Next Great Longevity Drug?

There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it. In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade. CHAPTERS: 00:00 — Introduction: The Blood Test Number Better Than Cholesterol 00:35 — What Is Lymphopenia and Why It Matters 01:50 — Immunosenescence: Why Your T Cells Decline After Age 20 02:30 — The Mortality Data: Three Studies on Lymphopenia 03:20 — Copenhagen Study: 63% Higher All-Cause Mortality 03:50 — Coronary Angiography Study: Hazard Ratio 1.97 04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells 05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer 06:00 — Four Hallmarks of Aging Hit By One Molecule 06:30 — ANKTIVA Explained: The IL-15 Super-Agonist 07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe 08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case 09:00 — The Skeptical Case: Why We Don't Know Yet 10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally 11:30 — Final Take and Closing KEY TAKEAWAYS: • Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studies • IL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancer • Resistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay young • ANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatment • IL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopenia • Honest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this space STUDIES & SOURCES MENTIONED: • Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES) — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2756114 • Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adults — https://pmc.ncbi.nlm.nih.gov/articles/PMC6957322/ • Bawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patients — https://pubmed.ncbi.nlm.nih.gov/33140390/ • FDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancer — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer ───────────────────────────────── 🔔 Subscribe for more evidence-based health insights 📖 Dr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/ 📰 Substack newsletter: https://robertlufkinmd.substack.com 🌐 Website: https://robertlufkinmd.com — **Enjoyed this episode?** Reviews on Apple Podcasts are the #1 way to help the show grow. Tap here to leave one in 30 seconds: https://podcasts.apple.com/us/podcast/health-longevity-secrets/id1585563694 #healthlongevity #lymphopenia #IL15 #anktiva #immunosenescence #robertlufkinmd